^
Association details:
| Biomarker: | ASXL1 Y588X |
|---|---|
| Cancer: | Myelodysplastic Syndrome |
| Drug: | alvocidib (DSP-2033) (CDK4 inhibitor, CDK6 inhibitor, CDK9 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
4380 ASXL1 Mutations Are Associated with a Response to the Combination of Alvocidib and 5-Azacytidine in Higher-Risk Myelodysplastic Syndromes
Published date:
11/03/2022
Excerpt:
However, the presence of ASXL1 mutations was significantly associated with higher cytotoxic activity of 5-AZA+Alv combination in univariable (p=0.0044) and multivariable (p=0.042) analyses….Increased sensitivity of BM cells to the cytotoxic effects of 5-AZA+Alv was also observed in Asxl1Y588XTg mice....We provided a pre-clinical rationale for the use of the 5-AZA+Alv combination for higher risks MDS and proposed ASXL1 mutations as potential genetic biomarkers of response in prospective clinical trials.
Secondary therapy:
azacitidine
DOI:
https://doi.org/10.1182/blood-2022-165298
